國立虎尾科技大學 |

Molecular Imaging in Multiple Myeloma

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Molecular Imaging in Multiple Myeloma/ edited by Cristina Nanni, Stefano Fanti, Lucia Zanoni.
其他作者:	Nanni, Cristina.
面頁冊數:	V, 136 p. 57 illus., 38 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Nuclear medicine. -
電子資源:	https://doi.org/10.1007/978-3-030-19019-4
ISBN:	9783030190194

Molecular Imaging in Multiple Myeloma
Molecular Imaging in Multiple Myeloma[electronic resource] /edited by Cristina Nanni, Stefano Fanti, Lucia Zanoni. - 1st ed. 2019. - V, 136 p. 57 illus., 38 illus. in color.online resource.

1.Multiple Myeloma: clinical aspects -- 2. What does a clinician need from new imaging procedures? -- 3.FDG PET in Multiple Myeloma -- 4. Role of Standard Magnetic Resonance Imaging -- 5.Whole Body Diffusion-Weighted Magnetic Resonance Imaging: A new era for whole body imaging in myeloma? -- 6.CXCR4 imaging in Multiple Myeloma -- 7.PET/CT with Standard NON-FDG Tracers -- 8. The issue of interpretation -- 9. Clinical Teachning Cases: FDG PET/CT .

This book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact. Other important features are the definition of criteria that will aid PET/CT interpretation; identification and explanation of the most frequent pitfalls; a brief overview of the advantages and limitations of DWI MR imaging, still an experimental technique in multiple myeloma; and examination of the possible role of emerging PET tracers. When appropriate, clinical cases are used to illustrate key teaching points. All physicians involved in oncological imaging should regularly reassess and update their routine practice in the evaluation of multiple myeloma patients. This is especially true now, given the recent clarification by the International Myeloma Working Group (IMWG) of the criteria for bone damage requiring therapy and the emerging data supporting the role of the newer functional imaging techniques in predicting outcome and/or evaluating response to therapy. In this challenging context, Molecular Imaging in Multiple Myeloma will be of high value for nuclear medicine physicians, radiologists, and hematologists.

ISBN: 9783030190194

Standard No.: 10.1007/978-3-030-19019-4doiSubjects--Topical Terms:

673902
Nuclear medicine.

LC Class. No.: R895-920

Dewey Class. No.: 616.07548

Molecular Imaging in Multiple Myeloma
LDR:02980nam a22003975i 4500 001 1005198
003 DE-He213
005 20200701185214.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783030190194 $9 978-3-030-19019-4
024 7 $a 10.1007/978-3-030-19019-4 $2 doi
035 $a 978-3-030-19019-4
050 4 $a R895-920
072 7 $a MMN $2 bicssc
072 7 $a MED080000 $2 bisacsh
072 7 $a MKR $2 thema
082 0 4 $a 616.07548 $2 23
245 1 0 $a Molecular Imaging in Multiple Myeloma $h [electronic resource] / $c edited by Cristina Nanni, Stefano Fanti, Lucia Zanoni.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a V, 136 p. 57 illus., 38 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a 1.Multiple Myeloma: clinical aspects -- 2. What does a clinician need from new imaging procedures? -- 3.FDG PET in Multiple Myeloma -- 4. Role of Standard Magnetic Resonance Imaging -- 5.Whole Body Diffusion-Weighted Magnetic Resonance Imaging: A new era for whole body imaging in myeloma? -- 6.CXCR4 imaging in Multiple Myeloma -- 7.PET/CT with Standard NON-FDG Tracers -- 8. The issue of interpretation -- 9. Clinical Teachning Cases: FDG PET/CT .
520 $a This book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact. Other important features are the definition of criteria that will aid PET/CT interpretation; identification and explanation of the most frequent pitfalls; a brief overview of the advantages and limitations of DWI MR imaging, still an experimental technique in multiple myeloma; and examination of the possible role of emerging PET tracers. When appropriate, clinical cases are used to illustrate key teaching points. All physicians involved in oncological imaging should regularly reassess and update their routine practice in the evaluation of multiple myeloma patients. This is especially true now, given the recent clarification by the International Myeloma Working Group (IMWG) of the criteria for bone damage requiring therapy and the emerging data supporting the role of the newer functional imaging techniques in predicting outcome and/or evaluating response to therapy. In this challenging context, Molecular Imaging in Multiple Myeloma will be of high value for nuclear medicine physicians, radiologists, and hematologists.
650 0 $a Nuclear medicine. $3 673902
650 0 $a Hematology. $3 645254
650 0 $a Oncology . $3 1253469
650 1 4 $a Nuclear Medicine. $3 673045
650 2 4 $a Oncology. $3 593951
700 1 $a Nanni, Cristina. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 890908
700 1 $a Fanti, Stefano. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 796628
700 1 $a Zanoni, Lucia. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1022704
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030190187
776 0 8 $i Printed edition: $z 9783030190200
776 0 8 $i Printed edition: $z 9783030190217
856 4 0 $u https://doi.org/10.1007/978-3-030-19019-4
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)